File No:BIO/CT/18/000047
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(Biological Division)

To,
M/s. MSD Pharmaceuticals Private Limited,6th Floor,
Tower B, Vatika Tower, Sector-54, Gurgaon Haryana (India) – 122002

Subject: Permission for conducting a Phase 4 clinical trial titled "A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects with Unresectable or Metastatic Melanoma or PD-L1 positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593)".

Reference:-Your Application No. BIO/Form44/FF/2018/9381 dated 13-JUL-2018 on the subject mentioned above

Sir,

This Directorate has no objection to your conducting subject mentioned study under the provisions of Drugs and Cosmetics Rules 122-DA and 122-DAC, under the supervision of the investigators mentioned below as per Protocol No.: MK-3475-593 Version No. 02 Protocol Date dated 17-MAY-2018 submitted to this Directorate.

S.No	Name Investigator	Clinical Trial Site address	Name and Address of the Ethics Committee
1	Dr Jyoti Bajpai	Tata Memorial Hospital, Room No. 1115, 11th Floor, Homi Bhabha Block, Dr. Ernest Borges Marg, Parel (E), Mumbai 400 012, Maharashtra, India	Institutional Ethics Committee-I, TATA Memorial Hospital, Main Building, 3rd Floor, Dr. Ernest Borges Road, Parel, Mumbai-400012 India" Registration No.ECR/170/Inst/M H/2013/RR-16
2	Dr P K Das	Indraprastha Apollo Hospitals, Sarita Vihar, Mathura Road, New Delhi-110076, India	Institutional Ethics Committee- Clinical Studies, Indraprastha Apollo Hospitals Sarita Vihar, New Delhi- 1100076, India, India Registration No. ECR/5/Inst/DL/20 13/RR-16
3	Dr D C Doval	Dept. of Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Sector-5, Rohini Delhi-110085	Institutional Review Board, Rajiv Gandhi Cancer Institute and Research Centre, Sector-5, Rohini, Delhi110085 Registration No. ECR/10/Inst/DL/2 013/RR-16
4	Dr Chetan Deshmukh	Deenanath Mangeshkar Hospital & Research Center, Near Mhatre Bridge, Erandawne, Pune, Maharashtra 411004, India	Institutional Ethics Committee; Department of Research 14 Floor C Wing Super Speciality building Deenanth mangeshkar Hospital and Research Centre off Karve Road Erandawane Pune-411004 Registration No. ECR/15/Inst/MH/ 2013/RR-16
5	Dr Hari Goyal	Artemis Hospitals, Sector 51, Gurgaon, Haryana-122001, India	Institutional Ethics Committee- Artemis Health Institute Sector-15 Gurgoan-122001 Haryana India Registration No. ECR/ 53/Inst/HR/2013/ RR-16
6	Dr Sewanti Atul Limaye	Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, 2nd Floor, Medical Research Department, Rao Saheb Achutrao Patwardhan Marg, Four Bunglows, Andheri West, Mumbai	Institutional Ethics Committee, Medical Research Department, 2nd Floor, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Rao Saheb Achutrao Patwardhan Marg, Four Bunglows, Andheri West, Mumbai-400053 Registration No. ECR/141/Inst/M H/2013/RR-16

7	Dr. Sadashivudu Gundeti	Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad, Telangana 500082, India	Institutional Ethics Committee Lokmanya Tilak Municipal Medical College 2nd Floor , Room No. 17 Sion Mumbai- 400022 Registration No. ECR/266/Inst/MH/2013 / RR2016

Licensing Authority as defined in clause (b) of Rule 21, issue permission for conduct of clinical trial, subject to the following conditions further, namely:-

(a) Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y annexed to these rules, Good Clinical Practice Guidelines for conduct of clinical trials in India and other applicable regulations;

(b) Approval of the Ethics Committee shall be obtained before initiation of the study;

(c) Clinical trial shall be registered at Clinical Trials Registry of India before enrolling the first patient for the study;

(d) Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority;

(e) Any report of serious adverse event occurring during clinical trial to the subject, after due analysis, shall be forwarded within fourteen days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y;

(f) In case of an injury or death during the clinical trial to the subject of the clinical trial the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with Rule 122 DAB and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority;

(g) The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trials in India and other applicable regulations;

(h) The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites and the investigator shall allow officers authorized by the Central Drug Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or without prior notice, any premises of sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, investigational drugs etc. related to clinical trials and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial;

(I)Submit complete report of clinical trials as per the approved protocol from the individual investigator duly signed by him along with his observations/remarks on the drug.

(j) Indicating the date of commencement and conclusion of the clinical trial at each center (in case the study is multicentric).

It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

It is informed that all the amendments to Rule 122DAA, inclusion of Rule 122DAB, compensation matters etc. that are appended to the Drugs & Cosmetics Act & Rule, vide GSR 53 (E) dated 30.01.2013 and in Part X-A, after Rule 122DAB, Rule 122 DAC vide GSR 63 (E) dated 01.02.2013 are mandatory and binding.

Yours faithfully,

S ESWARA REDDY

Digitally signed by S ESWARA REDDY
Date: 2018.11.22 17:15:30

(Dr. S. Eswara Reddy)
Drugs Controller General (I)